首页> 外文OA文献 >Phase 3 randomized study of adjuvant anastrozole (A), exemestane (E) or letrozole (L) with or without tamoxifen (T) in postmenopausal women with hormone-responsive (HR) breast cancer. The FATA-GIM3 trial

【2h】

Phase 3 randomized study of adjuvant anastrozole (A), exemestane (E) or letrozole (L) with or without tamoxifen (T) in postmenopausal women with hormone-responsive (HR) breast cancer. The FATA-GIM3 trial

机译：第3期随机研究佐剂Anstrozole（A），具有或不含Tamoxifen（T）的助剂患者，患有激素响应（HR）乳腺癌的泌胺血项（T）的氧化物（E）或Letrozole（L）。 FATA-GIM3试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
S. De Placido; C. Gallo; M. De Laurentiis; G. Bisagni; G. Arpino; M.G. Sarobba; F. Riccardi; A. Russo; L. Del Mastro; A. Cogoni; F. Cognetti; S. Gori; A. Frassoldati; D. Amoroso; L. Laudadio; L. Moscetti; F. Montemurro; F. Nuzzo; P. Carlini; F. Perrone;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial (vol 19, pg 474, 2018) [J] . De Placido S., Gallo C., De Laurentiis M. The lancet oncology . 2018,第4期

机译：佐剂Anastrozole与exemestane对letrozole，前期或2年后他莫昔芬，在内分泌敏感的乳腺癌（FATA-GIM3）：A随机，第3阶段试验（Vol 19，PG 474,2018）
2. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial [J] . De Placido Sabino, Gallo Ciro, De Laurentiis Michelino, The lancet oncology . 2018,第4期

机译：佐剂Anastrozole与大使与letrozole，前期或两年后的Tamoxifen，在内分泌敏感的乳腺癌（FATA-GIM3）：随机，第3阶段试验
3. Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study. [J] . Aihara T, Takatsuka Y, Ohsumi S, Breast cancer research and treatment. . 2010,第2期

机译：N-SAS BC03研究在日本绝经后的激素反应性乳腺癌女性中，单独使用他莫昔芬与序贯他莫昔芬和阿那曲唑的III期随机辅助研究：N-SAS BC03研究。
4. Study on the Efficacy Evaluation of Oral Sequential Tamoxifen in Postmenopausal Women with Hormone-dependent Breast Cancer [C] . Na Li, Yahua Sun, Sheng Zhao, International Conference on Life Sciences, Medicine, and Health . 2018

机译：激素依赖性乳腺癌后代妇女口腔序列儿毒素疗效评价研究
5. Is there an app for that? An exploratory randomized controlled trial of app-based mindfulness training for women with breast cancer. [D] . Rosen, Kristen D. 2016

机译：有针对这样的应用吗？基于应用程序的正念训练对乳腺癌女性的探索性随机对照试验。
6. Randomized Phase II Neoadjuvant Comparison Between Letrozole Anastrozole and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031 [O] . Matthew J. Ellis, Vera J. Suman, Jeremy Hoog, -1

机译：来曲唑阿那曲唑和依西美坦在雌激素受体丰富的第2至3期乳腺癌绝经后妇女中进行的随机II期新辅助治疗比较：基于基线PAM50的固有亚型ACOSOG Z1031的临床和生物标志物结果及预测价值
7. PCN6 A COST-EFFECTIVENESS ANALYSIS OF ADJUVANT THERAPY WITH EXEMESTANE, ANASTROZOLE, LETROZOLE OR TAMOXIFEN IN POSTMENOPAUSAL WOMEN WITH EARLYSTAGE BREAST CANCER IN MEXICO [O] . Mould-Quevedo J, Tapia-Valencia J, Davila-Loaiza G 2007

机译：PCN6在墨西哥绝经后早期乳腺癌患者中应用依西美坦，阿那曲唑，左氧唑或他莫昔芬辅助治疗的成本效益分析

Phase 3 randomized study of adjuvant anastrozole (A), exemestane (E) or letrozole (L) with or without tamoxifen (T) in postmenopausal women with hormone-responsive (HR) breast cancer. The FATA-GIM3 trial

著录项

相似文献

相关主题

期刊订阅